Vasomune announces financial support from the government for the development of COVID-19 therapeutics


Vasomune receives US $ 6.4 million PRMRP grant from US Department of Defense and up to US $ 2.8 million from NRC IRAP to support development of AV-001 for treatment of patients with severe COVID-19 disease and COVID-associated ARDS

TORONTO, November 08, 2021– (BUSINESS WIRE) – Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of diseases associated with vascular dysfunction, today announced that it has received a medical research program Peer Reviewed (PRMRP) Clinical Trial Grant (CTA) in the amount of US $ 6.4 million from the US Department of Defense (DOD). In addition, the company receives consulting services and research and development funding of up to $ 2.8 million from the Industrial Research Assistance Program of the National Research Council of Canada (NRC IRAP).

“We are extremely grateful for the financial support of the Congress-led DOD (CDMRP) PRMRP and NRC IRAP congress-led medical research programs which will enable Vasomune to accelerate the clinical development of AV-001,” said Douglas A. Hamilton , President and CEO of Vasomune. “Preclinical data suggests that the mechanism of action of AV-001 has the potential to reduce the mortality and morbidity of SARS-CoV-2, including the emergence of new variants. “

“Our strategic approach to SARS-CoV-2 involves the development of AV-001 for the treatment of patients with severe COVID-19 disease and vaccines to prevent infection,” said Ei Yamada, President and CEO General AnGes, Inc., the co-development of Vasomune partner, “We very much appreciate government grants that will help accelerate the clinical development of AV-001. “

The Vasomune grant was received from the PRMRP and awarded effective September 1, 2021. The Vasomune Clinical Development Program for AV-001 received an application score of “Excellent” or 1.6 on a scale of 1 to 5 Through a rigorous two-tier peer review system in 13.8% of all invited applicants receive funding recommendations. Funding from the PRMRP award will be used to support the phase 2a study of AV-001 in patients hospitalized with severe COVID-19 disease. The opinions, interpretations, conclusions and recommendations are those of the author and not necessarily endorsed by the Ministry of Defense.

NRC IRAP funding, originally planned at $ 1.2 million, was changed on August 25, 2021, bringing the total level of funding to $ 2.8 million. Funding from the NRC IRAP program will support Phase 1 clinical development and other studies required for Clinical Trial Application (CTA) submission to Health Canada.

About AV-001

Originally discovered and designed at Sunnybrook Hospital in Toronto, AV-001 is developed by Vasomune Therapeutics, Inc. under a co-development agreement with AnGes, Inc. [TYO: 4563]. AV-001 is an investigational new drug that targets the Tie2 receptor, a transmembrane target protein most highly expressed on the surface of endothelial cells in the vascular system.

AV-001 activates the non-redundant Tie2-angiopoietin signaling axis and, through stimulation of several downstream pathways, restores normal vascular function and endothelial stability. Vascular dysfunction contributes to the pathophysiology of the underlying disease in patients with COVID-19, including respiratory distress, hypercoagulopathy, viral sepsis, myocardial inflammation, and acute kidney injury, particularly in patients with patients with pre-existing vascular comorbidities, such as hypertension, diabetes and obesity. New evidence suggests that SARS-CoV-2 infects lung endothelial cells and causes microvascular leakage, contributing to the initiation and spread of respiratory distress in COVID-19 patients by altering the integrity of the blood vessels, promoting a state of coagulation and inducing vascular inflammation (endotheliitis). In preclinical studies involving an animal model of infection with a deadly influenza RNA virus,

AV-001 has been shown to stabilize the vascular system by improving the stability of endothelial cells, restoring a normal defense barrier and blocking vascular leakage. Importantly, AV-001 monotherapy significantly improved survival and lung function compared to untreated controls and showed the benefit of improved recovery in combination with antiviral therapy.

About Vasomune Therapeutics, Inc.

Vasomune Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company developing the next generation of drugs to harness the body’s ability to defend itself against disease. Originally founded in 2014, Vasomune discovers and develops drugs using a novel therapeutic approach focused on vascular normalization strategies. Vascular dysfunction is associated with the pathology of several disease states, including COVID-19, viral and bacterial pneumonia, acute renal failure, glaucoma, hemorrhagic shock, sepsis, stroke and associated complications to diabetes. Vasomune’s corporate headquarters and laboratories are located in Toronto, Canada, with offices in the United States in San Mateo, California. For more information on the company and its product candidates, please visit www.vasomune.com.

About Angels, Inc.

AnGes, Inc., a biopharmaceutical company founded in December 1999, focuses on the development of gene-based drugs. In March 2019, AnGes obtained conditional and time-limited approval of its flagship product, Collategene® (Hepatocyte Growth Factor; HGF — plasmid gene therapy), for the treatment of ischemic ulcers of the lower limbs. In September 2019, AnGes began the marketing in Japan of Collategene®, the first drug marketed in the world using plasmid DNA. AnGes is currently working on the development of DNA vaccines for COVID-19 and hypertension, a Tie2 tyrosine kinase receptor agonist (AV-001) for the treatment of COVID-19 and a decoy oligonucleotide NF-κB for low back pain. chronic disc. Additionally, AnGes acquired EmendoBio in December 2020 to expand its capabilities in genome editing technologies. For more information, visit https://www.anges.co.jp/en/.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211108005450/en/

Contacts

Media:
Shahid Ahmad
Vasomune media relations
(647) 475-5663
[email protected]


Comments are closed.